| 634 article results |
|
-
Contributor: Gerald Clarke
Posted: 05/23/2013 12:00:00 AM EDT | 0
Most people have received an email promising male sexual enhancement pills, recently the FDA and the EU have led concerted efforts to battle online drug fraud. Now industry is making steps in this direction, read about this new and interesting development. Read more
-
Contributor: Gerald Clarke
Posted: 05/20/2013 12:00:00 AM EDT | 0
The controversy surrounding the impending release of the DSM-5 may have spurred on one of the most interesting developments in psychiatric medicine in decades. Our editor investigates the controversy and asks what's next for the world's most influential diagnostic manual. Read more
-
Contributor: Gerald Clarke
Posted: 05/17/2013 12:00:00 AM EDT | 0
Drug design is growing up. Sophisticated, standardised, smart methods of developing new chemical entities (NCEs) are now the order of the day. No Topic shows this better than drug transporter proteins. Read about the latest research on this hot topic. Read more
-
Contributor: Gerald Clarke
Posted: 05/16/2013 12:00:00 AM EDT | 0
Angelina Jolie published an op-ed in the New York Times about her decision to undergo a preventative double mastectomy in response to learning that she carried a defective version of the BRCA1 gene has banished all doubt that we are living in a post-genomic world. Our editor explores the issues raised in this story Read more
-
Contributor: Cold Chain IQ
Posted: 05/14/2013 12:00:00 AM EDT | 0
In January this year the Chinese State Food and Drug Administration (SFDA) published a newly revised Good Supply Practice for Pharmaceutical Products (GSP), which will go into effect as of June 1, 2013. The revised guidance sets higher qualification requirements, increases standards for drug distribution and also has higher requirements for quality management. Read more
-
Contributor: Cold Chain IQ
Posted: 05/14/2013 12:00:00 AM EDT | 0
Brazil’s National Health Surveillance Agency (Anvisa) opened a consultation on the 4th April to propose the formation of an electronic tracking system for drugs from point of production through to the point of dispensing to the patient. Read more
-
Contributor: Gerald Clarke
Posted: 05/14/2013 12:00:00 AM EDT | 0
In a move which has baffled some and angered others, Canada Health has approved influenzinium, a nosode as a vaccine for flu. At a time that many consider critical for public health and vaccination programs, this move has caused outrage in the scientific community. Our editor inspects the issues surrounding this controversial topic. Read more
-
Contributor: Gerald Clarke
Posted: 05/13/2013 12:00:00 AM EDT | 0
The old argument of nature vs nurture has been known to be a false dilemma for a long time, the true making of an organism lies in both and no topic illustrates this better than epigenetics. What is epigenetics and why is it important? In this introduction we explore the history and principles of this blossoming field. Read more
-
Contributor: Gerald Clarke
Posted: 05/10/2013 12:00:00 AM EDT | 0
In a fiscally constrained environment it is unsurprising that one of the lightening rods has been drug pricing. In this article, we explore 4 of the biggest battles that have erupted on this contentious topic in recent years. Let us know where you think these battles are headed and what can be done to resolve them. Read more
| 634 article results |
|
-
Compound Management & Integrity Online 2011
November 14, 2011
Register Now -
Regenerative Medicine and Barriers to Commercialisation Online Summit 2011
October 25, 2011
Register Now -
Electronic Laboratory Notebooks Online
December 2, 2011
Register Now -
Drive Successful Commercial Product Launches through Effective Key Packaging
February 7, 2013
Register Now
-
Intellectual Property Protection Solutions for Pharma and Biotech - Part 2
out licensing | outlicensing | Brainloop
-
Pharmaceutical Jobs Insight
pharma jobs | pharmaceutical jobs | pharmaceutical jobs market
-
Two Reasons Why Small to Mid-Sized Biotechs Can't Get Financing in a Biotech Boom
biotechs | Ernst & Young report | biotech boom




Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!